Mitochondrial p53 Contributes to Reovirus-Induced Neuronal Apoptosis and Central Nervous System Injury in a Mouse Model of Viral Encephalitis.
The tumor suppressor p53 plays a critical part in determining cell fate both as a regulator of the transcription of several proapoptotic genes and through its binding interactions with Bcl-2 family proteins at mitochondria. We now demonstrate that p53 protein levels are increased in infected brains during reovirus encephalitis. This increase occurs in the cytoplasm of reovirus-infected neurons and is associated with the activation of caspase 3. Increased levels of p53 in reovirus-infected brains are not associated with increased expression levels of p53 mRNA, suggesting that p53 regulation occurs at the protein level. Increased levels of p53 are also not associated with the increased expression levels of p53-regulated, proapoptotic genes. In contrast, upregulated p53 accumulates in mitochondria. Previous reports demonstrated that the binding of p53 to Bak at mitochondria causes Bak activation and results in apoptosis. We now show that Bak is activated and that activated Bak is bound to p53 during reovirus encephalitis. In addition, survival is enhanced in reovirus-infected Bak(-/-) mice compared to controls, demonstrating a role for Bak in reovirus pathogenesis. Inhibition of the mitochondrial translocation of p53 with pifithrin μ prevents the formation of p53/Bak complexes following reovirus infection of ex vivo brain slice cultures and results in decreased apoptosis and tissue injury. These results suggest that the mitochondrial localization of p53 regulates reovirus-induced pathogenesis in the central nervous system (CNS) through its interactions with Bak.



There are virtually no specific treatments of proven efficacy for virus-induced neuroinvasive diseases. A better understanding of the pathogenesis of virus-induced CNS injury is crucial for the rational development of novel therapies. Our studies demonstrate that p53 is activated in the brain following reovirus infection and may provide a therapeutic target for virus-induced CNS disease.
Department of Neurology, University of Colorado Denver, Aurora, Colorado, USA.
Yonghua
Y
Zhuang
Internal Medicine Residency Program and Physician Scientist Training Program, University of Colorado Denver, Aurora, Colorado, USA.
Heather M
HM
Berens-Norman
Department of Neurology, University of Colorado Denver, Aurora, Colorado, USA.
J Smith
JS
Leser
Department of Neurology, University of Colorado Denver, Aurora, Colorado, USA Penny.Clarke@ucdenver.edu.
Penny
P
Clarke
Department of Neurology, University of Colorado Denver, Aurora, Colorado, USA Department of Immunology and Microbiology, University of Colorado Denver, Aurora, Colorado, USA Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA Denver VA Medical Center, Denver, Colorado, USA.
Kenneth L
KL
Tyler
D000818:Animals; D017209:Apoptosis; D004195:Disease Models, Animal; D018792:Encephalitis, Viral / Q000473:pathology* / Q000821:virology; D054884:Host-Pathogen Interactions; D051379:Mice; D008928:Mitochondria / Q000378:metabolism; D009474:Neurons / Q000473:pathology / Q000821:virology*; D011485:Protein Binding; D025941:Protein Interaction Mapping; D012087:Reoviridae / Q000472:pathogenicity*; D012088:Reoviridae Infections / Q000473:pathology* / Q000821:virology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D015854:Up-Regulation; D050998:bcl-2 Homologous Antagonist-Killer Protein / Q000378:metabolism*
C494773:Bak1 protein, mouse; D016159:Tumor Suppressor Protein p53; D050998:bcl-2 Homologous Antagonist-Killer Protein